<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830228</url>
  </required_header>
  <id_info>
    <org_study_id>C1903</org_study_id>
    <nct_id>NCT04830228</nct_id>
  </id_info>
  <brief_title>BIOTRONIK Dynetic-35 Stent for the Treatment of Peripheral Iliac Lesions</brief_title>
  <acronym>BIONETIC-I</acronym>
  <official_title>BIOTRONIK Dynetic-35 for the Treatment of Peripheral Iliac Lesions, Using the Cobalt Chromium Balloon-expandable Dynetic-35 Stent in Association With Passeo-35 Xeo Peripheral Dilation Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIOTRONIK cobalt chromium balloon-expandable Dynetic-35 stent in association with Passeo-35&#xD;
      Xeo peripheral dilation catheter for the treatment of peripheral iliac lesions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, international, multi-center, single-arm study with up to 60 months follow up to&#xD;
      evaluate safety and effectiveness of BIOTRONIK's Dynetic-35 stent associated with the use of&#xD;
      Passeo-35 Xeo for the treatment of peripheral artery disease (PAD) in subjects with&#xD;
      atherosclerotic disease in iliac arteries&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">September 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MAE at 12 months post-index procedure.</measure>
    <time_frame>12 Months</time_frame>
    <description>The MAE includes device or procedure related death within 30 days post index procedure, cdTLR, and major index limb amputation up to 12 months post index procedure.</description>
  </primary_outcome>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ballon expandable stent and PTA</intervention_name>
    <description>Endovascular treatment for the peripheral artery disease of the Iliac artery</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll subjects who have peripheral artery disease (PAD) requiring&#xD;
        endovascular treatment of de-novo, restenotic and in-stent atherosclerotic lesions in iliac&#xD;
        arteries&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is ≥ 18 years or the minimum age required for legal adult consent in the&#xD;
             country of enrolment&#xD;
&#xD;
          2. Subject is capable (no legally authorized representative allowed) to provide written&#xD;
             informed consent as approved by the Institutional Review Board (IRB)/Ethics Committee&#xD;
             (EC) of the respective clinical site prior to any study related procedure&#xD;
&#xD;
          3. Subject has provided written informed consent before any study specific test or&#xD;
             procedure and is willing to comply with all protocol and follow-up requirements&#xD;
&#xD;
          4. De novo, restenotic, occluded or in-stent lesion(s) representing atherosclerotic&#xD;
             lesion(s) in the iliac arteries&#xD;
&#xD;
          5. Reference lumen (vessel) diameter between 5mm and 10 mm&#xD;
&#xD;
          6. The target lesion can be successfully crossed with a guide wire&#xD;
&#xD;
          7. The target lesion length is ≤ 100 mm&#xD;
&#xD;
          8. Subjects has more than 70% stenosis in target lesion&#xD;
&#xD;
          9. Subject has an evidence of a patent profunda femoris or superficial femoral artery in&#xD;
             the target limb or limbs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is pregnant and/or breastfeeding or planning to become pregnant during the&#xD;
             course of the study.&#xD;
&#xD;
          2. Subject is with a current medical condition with a life expectancy of less than one&#xD;
             year.&#xD;
&#xD;
          3. Pre-existing target iliac artery aneurysm or perforation or dissection of the target&#xD;
             iliac artery&#xD;
&#xD;
          4. Any medical condition that in the opinion of the investigator poses an unacceptable&#xD;
             risk for implant of a stent according to the study indications like, sensitivity to&#xD;
             metal ions, has intolerance to contrast or antiplatelet, anticoagulant or thrombolytic&#xD;
             medications required per the protocol&#xD;
&#xD;
          5. Abdominal aortic aneurysm (AAA) contiguous to the iliac artery target lesion requiring&#xD;
             EVAR (Endovascular Aneurysm Repair) treatment&#xD;
&#xD;
          6. The subject is currently participating in an investigational drug, biologic, or&#xD;
             another device study and has not reached their primary endpoint yet.&#xD;
&#xD;
          7. Refuses blood transfusion&#xD;
&#xD;
          8. Chronic renal insufficiency (eGFR &lt; 30 mL/min within 72 hours prior to index&#xD;
             procedure)&#xD;
&#xD;
          9. Subject has IFU listed contraindication(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Brodmann, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Substitute Head of the Clinical Division of Angiology, Department of Internal Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natasha Joshi, Dr</last_name>
    <phone>0 44 864 54 90</phone>
    <phone_ext>+41</phone_ext>
    <email>natasha.joshi@biotronik.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LKH Univ.-Klinikum Graz, Ambulanz für Angiologie</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianne Brodmann, Prof Dr</last_name>
    </contact>
    <contact_backup>
      <last_name>Eva Pock</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Heilig Hart Tienen</name>
      <address>
        <city>Tienen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Koen Keirse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iliac arteries</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

